Knight Therapeutics (TSE:GUD) Sets New 1-Year High – Here’s What Happened

Knight Therapeutics Inc. (TSE:GUD)’s share price hit a new 52-week high on Monday . The company traded as high as C$9.98 and last traded at C$9.98, with a volume of 21477 shares changing hands. The stock had previously closed at C$9.91.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$9.50 target price on shares of Knight Therapeutics and gave the stock a “buy” rating in a research report on Friday, May 8th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of C$9.50.

Knight Therapeutics Trading Down 0.3%

The firm has a market capitalization of C$977.86 million, a P/E ratio of 166.00, a P/E/G ratio of -1,013.50 and a beta of -0.21. The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86. The stock has a 50 day simple moving average of C$8.76 and a 200-day simple moving average of C$7.25.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, May 7th. The company reported C$0.13 earnings per share for the quarter. The firm had revenue of C$147.59 million for the quarter. Knight Therapeutics had a net margin of 1.10% and a return on equity of 0.73%. On average, equities research analysts forecast that Knight Therapeutics Inc. will post 0.1009486 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.